Is OSCR a Buy? What to Consider in 2026
Short answer
The bull case for Oscar Health (OSCR) rests on Membership growth and share gains: Oscar grew to about 3.2 million members in early 2026, roughly 56% higher than a year earlier, expanding faster than the overall ACA marketplace. Revenue (TTM) is ~$13 billion. If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: The dominant risk is policy. Whether OSCR is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
Oscar Health is a US health insurance company built around a digital-first member experience rather than the paperwork and call centers of legacy insurers. The vast majority of its money comes from premiums on individual and family health plans sold through the Affordable Care Act (ACA) public marketplaces, where by early 2026 it had grown to roughly 3.2 million members, up about 56% year over year, making it one of the larger players on the exchanges. Alongside the insurance business it runs +Oscar, a technology platform it licenses to other healthcare organizations, plus brokerage and enrollment tools; that platform revenue is small today but growing faster than premiums and carries higher margins. The company was founded in 2012 by Mario Schlosser, Kevin Nazemi, and Joshua Kushner, and is now led by chief executive Mark Bertolini, a former Aetna CEO. The investment picture in 2026 is a profitability turnaround meeting a policy overhang. After years of losses, Oscar posted a record first quarter (revenue of roughly $4.65 billion, up more than 50% year over year, and net income near $679 million) as its medical loss ratio improved and enrollment surged, and the stock roughly doubled to near multi-year highs. But Oscar is essentially a pure-play ACA insurer, which makes it unusually sensitive to the enhanced premium tax credits that made marketplace coverage cheap for millions; those subsidies are set to lapse, and if they are not extended, enrollment and the health of the risk pool could deteriorate. The result is a stock that can move sharply on legislative headlines, so how you think about it depends heavily on your view of ACA policy and your tolerance for that binary risk.
What's the case for buying OSCR?
1. Membership growth and share gains
Oscar grew to about 3.2 million members in early 2026, roughly 56% higher than a year earlier, expanding faster than the overall ACA marketplace. Each net-new member adds premium revenue, and the company has entered new states and counties to widen its footprint. The bet is that a simpler digital experience keeps winning enrollees from legacy carriers.
2. Turn to profitability
After years of losses, Oscar reached record profitability, reporting Q1 2026 net income near $679 million and an improving medical loss ratio of about 70.5%, down roughly 490 basis points year over year. Management reaffirmed full-year guidance for earnings from operations of $250 million to $450 million. Sustained profit, if it holds through the seasonally heavier back half, is the core of the re-rating story.
3. The +Oscar technology platform
Beyond selling insurance, Oscar licenses its +Oscar technology stack (claims automation, member engagement, care navigation) to other healthcare organizations. This platform revenue is still a small slice but grows faster than premiums and carries higher margins, giving Oscar a second, less capital-intensive line that is not purely a bet on the ACA marketplace.
4. Operating leverage and automation
Oscar leans on automation, citing very high claims auto-adjudication rates, to run leaner than traditional insurers. Its SG&A ratio improved toward roughly 15% as membership scaled. If it can keep administrative costs falling as a share of revenue while enrollment grows, incremental premium dollars should convert to profit at a higher rate than for slower peers.
What are the risks to OSCR?
The dominant risk is policy. Oscar is a near pure-play ACA marketplace insurer, so the scheduled expiration of enhanced federal premium tax credits is an existential-level variable: if the credits are not extended, marketplace premiums could more than double for many enrollees, healthier members may drop coverage, and the remaining risk pool would skew sicker and more expensive. Oscar itself took a weighted-average rate increase near 28% for 2026 partly to account for worsening morbidity. Results are also highly seasonal and can be volatile, swinging from strong first-quarter profit to losses later in the year as the medical loss ratio climbs; full-year MLR is guided well above the Q1 figure. On top of that, Oscar competes against far larger, better-capitalized insurers, and any spike in medical costs, adverse regulatory change, or execution stumble hits a company still proving it can stay consistently profitable.
How is OSCR valued? (as of July 2026)
Snapshot for OSCR as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (TTM): ~$13 billion
- Revenue (Q1 2026 quarterly): ~$4.65 billion, up ~53% year over year
- Net income (Q1 2026): ~$679 million, or ~$2.07 per diluted share, a record
- Members: ~3.2 million, up ~56% year over year
- FY2026 revenue guidance: ~$18.7 billion to ~$19 billion
- Market cap: ~$8.6 billion (stock ~$32 per share)
Figures are approximate and tied to the asOf date; verify live numbers before acting. OSCR roughly doubled in 2026 to near multi-year highs after its record first quarter, yet it still trades at a low price-to-sales ratio (around 0.5x) versus other insurers because the market prices in ACA-policy risk and the possibility that back-half losses offset early-year profit. The valuation is less a bet on a rich growth multiple and more a wager on whether the profitability turn is durable through a policy shock.
How do you decide if OSCR is a buy?
Rather than asking whether OSCR is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold OSCR indirectly through an index or sector ETF before adding more.
For the full picture, see the OSCR stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about OSCR against your real portfolio and see your actual exposure before deciding.
The bottom line on OSCR
The bottom line: Oscar Health's story right now is Membership growth and share gains, with revenue (ttm) at ~$13 billion. If you believe that narrative continues, the call is about sizing OSCR sensibly and checking overlap with what you own; if you doubt it (the risk: the dominant risk is policy.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
Build a basket around OSCR with Walnut
Use Oscar Health as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is OSCR a good stock to buy right now?
+
The case for Oscar Health right now is Membership growth and share gains, with revenue (ttm) at ~$13 billion. If you believe that thesis holds, OSCR is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is the dominant risk is policy. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does Oscar Health do?
+
Oscar Health is a US health insurance company built around a digital-first member experience rather than the paperwork and call centers of legacy insurers.
What are the main risks of OSCR?
+
The dominant risk is policy. Oscar is a near pure-play ACA marketplace insurer, so the scheduled expiration of enhanced federal premium tax credits is an existential-level variable: if the credits are not extended, marketplace premiums could more than double for many enrollees, healthier members may drop coverage, and the remaining risk pool would skew sicker and more expensive. Oscar itself took a weighted-average rate increase near 28% for 2026 partly to account for worsening morbidity. Results are also highly seasonal and can be volatile, swinging from strong first-quarter profit to losses later in the year as the medical loss ratio climbs; full-year MLR is guided well above the Q1 figure. On top of that, Oscar competes against far larger, better-capitalized insurers, and any spike in medical costs, adverse regulatory change, or execution stumble hits a company still proving it can stay consistently profitable.
Is OSCR a good stock to buy right now?
+
That depends on your goals, time horizon, and risk tolerance, and this is not investment advice. The bull case is a real turn to profitability, fast membership growth, and a technology platform that runs leaner than legacy insurers. The bear case is that Oscar is a near pure-play ACA insurer whose earnings hinge on federal subsidy policy, with volatile, seasonal results. Weigh both against your own portfolio.
What does Oscar Health do?
+
Oscar Health is a US health insurance company that sells individual and family health plans, primarily through the Affordable Care Act marketplaces, with a digital-first member experience. Most of its revenue comes from insurance premiums. It also runs +Oscar, a technology platform it licenses to other healthcare organizations, plus brokerage and enrollment services.
Why did OSCR stock rise so much in 2026?
+
The stock roughly doubled in 2026 after Oscar reported a record first quarter, with revenue up more than 50% year over year, net income near $679 million, and an improving medical loss ratio. Membership surged about 56%, and management reaffirmed full-year profit guidance. Optimism about a possible extension of ACA subsidies also lifted the shares on several occasions.
What is the biggest risk with Oscar Health?
+
Policy is the central risk. Oscar is a near pure-play ACA marketplace insurer, so it is unusually exposed to the enhanced federal premium tax credits that are set to lapse. If those subsidies are not extended, premiums could spike, healthier members may leave, and the remaining risk pool would worsen. That makes the stock sensitive to legislative headlines.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell OSCR; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.